


# Early identification of brain damage complications and infections in hospitalized patients with blood-based biomarker tests

Novel blood biomarkers to accurately predict post-brain damage infections earlier and allow optimal prevention or treatment strategy.

## Facts about post-brain injury complications

Ischemic stroke, intracerebral (ICH) or subarachnoidal hemorrhage (SAH) and traumatic brain injury are the main acute brain damage events.

Infection represents the most common post-brain injury complication and can dramatically worsen patients' outcomes and mortality.



*Pneumonia, is among the most common post-stroke complications*

## Current situation

Such complications are currently treated only when they are symptomatic and diagnosed, and in this group of patients, it can mean delayed therapeutic decisions. Although preventive antibiotic therapy is safe, the likelihood of boosting antibiotic resistance in bacteria needs to be taken into account and is therefore, not used widely.

Thus, identification of novel blood biomarkers indicating post-brain damage complications will allow the optimal prevention or treatment strategy to be chosen rapidly. Thus, it represents a very significant step forward and opens the door to improved patient care with better outcomes.

Unfortunately, inflammatory markers (such as CRP, white blood cell count, etc.) and other clinical and radiological signs, are often only detected after the establishment of infection, with a subsequent delay in antibiotic treatment.

## ABCDx Value Proposition

- ABCDx has identified biomarker panels including Serum Amyloid A (SAA), which offer the potential of a **more tailored approach** to preventive antibiotic therapy, identifying patients at a high risk of post-brain damage infections and thus increasing the efficacy of antibiotic

therapy by allowing treatments to be implemented more rapidly on patients at risk.

- Based on current cohort studies, ABCDx biomarker panels reveal that infection can be predicted 2-3 days earlier, including at admission for half of the patients. We anticipate the ABCDx panels to fit into the routine daily monitoring of Stroke Units and ICU patients following brain injury.

## Intellectual Property status

ABCDx secured exclusive commercial rights to families of patent applications protecting the use of multiple-parametric tests for patients presenting with symptoms of brain injury.

This IP places ABCDx as a leading company offering new approaches to assessing clinical decisions and rapidly selecting therapeutic intervention, even in decentralised locations.

*Biomarker Panels for Brain Injury Complications  
WO 2017/008894 A1*

## Company overview & Licensing opportunities

- ABCDx is a company dedicated to transforming brain injury care by the use of biomarker panel tests for the assessment and indication in patients suffering from mild traumatic injury to stroke and post-stroke complications.
- ABCDx seeks to partner with companies developing and marketing diagnostic tests for appropriate markers, as well as pharmaceutical companies seeking to increase the use of therapies earlier and to a greater proportion of eligible patients.

